强生Nipocalimab达到2期临床主要终点，用于治疗SjD

Investment Ratings - The report does not provide specific ratings for the chemical pharmaceuticals and traditional Chinese medicine sectors, while the biopharmaceutical sector is rated as neutral and other medical therapies are also rated neutral [1][2]. Core Insights - The pharmaceutical sector experienced a decline of 0.51% on June 18, 2024, underperforming the CSI 300 index by 0.78 percentage points, ranking 30th among 31 sub-industries. The best-performing sub-industries included medical circulation (+0.64%) and offline pharmacies (+0.30%), while medical research outsourcing (-2.55%), vaccines (-1.56%), and blood products (-1.12%) lagged behind [2]. - Johnson & Johnson's investigational antibody therapy Nipocalimab achieved its primary endpoint in a Phase 2 clinical trial for treating Sjögren's syndrome (SjD), showing statistically significant improvement in the ClinESSDAIa score at week 24 compared to baseline (P=0.002). Nipocalimab is a potential BIC-targeting FcRn antibody therapy that has received breakthrough therapy designation from the FDA [3][6]. Summary by Sections Market Performance - As of June 18, 2024, the pharmaceutical sector's performance was -0.51%, underperforming the CSI 300 index by 0.78 percentage points, with notable performances from medical circulation and offline pharmacies [2]. Industry News - Johnson & Johnson's Nipocalimab reached its primary endpoint in a Phase 2 trial for SjD, indicating a significant clinical improvement [3][6]. Company Announcements - HuLuWa (605199) received approval for Montelukast Chewable Tablets for asthma treatment in children aged 2 to 14 [4]. - Baiyunshan (600332) announced that its subsidiary received approval for Dopamine Hydrochloride Injection after passing consistency evaluation [4]. - Haizheng Pharmaceutical (600267) reported that its subsidiary received approval for Cladribine Injection after consistency evaluation [4]. - Northeast Pharmaceutical (000597) announced that its Vitamin C raw material has passed the European Pharmacopoeia suitability certificate, allowing sales in the EU high-end pharmaceutical market [4].